MarketPulse
K

$KYMR

2 articles found
1 positive
0 negative
1 neutral
The Motley FoolThe Motley Fool··Jonathan Ponciano

Major Hedge Fund Exits Protagonist Position Despite 120% Stock Surge

BVF Partners liquidated its $170M Protagonist stake despite 120% gains, likely due to changing risk profile as company awaits FDA decision on blood disorder treatment.
PTGXKYMRRVMDRVMDWclinical-stage biotechhedge fund liquidation
The Motley FoolThe Motley Fool··Jonathan Ponciano

BVF's $52M Stake in Disc Medicine Signals Confidence Despite Regulatory Hurdles

BVF Partners invests $52M in Disc Medicine despite FDA setbacks, betting on Phase 3 trial data and strong cash reserves through 2029.
KYMRRVMDRVMDWIRONFDA approvalclinical trial